Piper Sandler on Praxis Precision Medicines (PRAX): 'Two Major Wins Set the Stage for Multiple Potential Approvals in 2026'
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $450.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)